Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa)

Blood

Volumn 119, Issue 6, 2012, Pages 1418-1427

  Couzi, Lionel ^a,b,c   Pitard, Vincent ^a,b   Sicard, Xavier ^a,b   Garrigue, Isabelle ^a,c   Hawchar, Omar ^a,b   Merville, Pierre ^a,b,c   Moreau, Jean François ^a,b,c   Déchanet Merville, Julie ^a,b  

^a CNRS Bordeaux Segalen University   (France)

^b CNRS   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD16 ANTIGEN; CYTOMEGALOVIRUS ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED PATIENT; IN VITRO STUDY; LYMPHOCYTE FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIROGENESIS;

EID: 84856869951     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-363655     Document Type: Article

References (42)

1. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22(1):76-98.
2. Isaacson MK, Juckem LK, Compton T. Virus entry and innate immune activation. Curr Top Microbiol Immunol. 2008;325:85-100.
3. Revello MG, Gerna G. Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications. Rev Med Virol. 2010;20(3):136-155.
4. Potzsch S, Spindler N, Wiegers AK, et al. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog. 2011;7(8):e1002172.
5. Bjorkstrom NK, Gonzalez VD, Malmberg KJ, et al. Elevated numbers of Fc gamma RIIIA+(CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection. J Immunol. 2008;181(6):4219-4228.
6. Clemenceau B, Vivien R, Berthome M, et al. Effector memory alphabeta T lymphocytes can express FcgammaRIIIa and mediate antibody-dependent cellular cytotoxicity. J Immunol. 2008;180(8):5327-5334.
7. Lanier LL, Kipps TJ, Phillips JH. Functional properties of a unique subset of cytotoxic CD3+T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen). J Exp Med. 1985;162(6):2089-2106. (Pubitemid 16149696)
8. Braakman E, van de Winkel JG, van Krimpen BA, Jansze M, Bolhuis RL. CD16 on human gamma delta T lymphocytes: expression, function, and specificity for mouse IgG isotypes. Cell Immunol. 1992;143(1):97-107.
9. Tokuyama H, Hagi T, Mattarollo SR, et al. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs-rituximab and trastuzumab. Int J Cancer. 2008;122(11):2526-2534. (Pubitemid 351590486)
10. Lafont V, Liautard J, Liautard JP, Favero J. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen. J Immunol. 2001;166(12):7190-7199. (Pubitemid 32525592)
11. Angelini DF, Borsellino G, Poupot M, et al. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood. 2004;104(6):1801-1807. (Pubitemid 39202290)
12. Gertner-Dardenne J, Bonnafous C, Bezombes C, et al. Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies. Blood. 2009;113(20):4875-4884.
13. Wu Y, Wu W, Wong WM, et al. Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol. 2009;183(9):5622-5629.
14. Dechanet J, Merville P, Lim A, et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest. 1999;103(10):1437-1449. (Pubitemid 29535500)
15. Pitard V, Roumanes D, Lafarge X, et al. Long term expansion of effector/memory V delta2neg gammadelta T cells is a specific blood signature of CMV infection. Blood. 2008;112(4):1317-1324.
16. Couzi L, Pitard V, Netzer S, et al. Common features of gammadelta T cells and CD8(+) alpha-beta T cells responding to human cytomegalovirus infection in kidney transplant recipients. J Infect Dis. 2009;200(9):1415-1424.
17. Halary F, Pitard V, Dlubek D, et al. Shared reactivity of Vdelta2(neg) gammadelta T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells. J Exp Med. 2005;201(10):1567-1578. (Pubitemid 40721002)
18. Lafarge X, Merville P, Cazin MC, et al. Cytomegalovirus infection in transplant recipients resolves when circulating gammadelta T lymphocytes expand, suggesting a protective antiviral role. J Infect Dis. 2001;184(5):533-541. (Pubitemid 32783542)
19. Couzi L, Levaillant Y, Jamai A, et al. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol. 2010;21(1):181-188.
20. Knight A, Madrigal AJ, Grace S, et al. The role of Vdelta2-negative gamma-delta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplants. Blood. 2010;116(12):2164-2172.
21. de Villartay JP, Lim A, Al-Mousa H, et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J Clin Invest. 2005;115(11):3291-3299. (Pubitemid 41567594)
22. Vermijlen D, Brouwer M, Donner C, et al. Human cytomegalovirus elicits fetal gammadelta T cell responses in utero. J Exp Med. 2010;207(4):807-821.
23. Puig-Pey I, Bohne F, Benitez C, et al. Characterization of gammadelta T cell subsets in organ transplantation. Transpl Int. 2010;23(10):1045-1055.
24. Karrer U, Sierro S, Wagner M, et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol. 2003;170(4):2022-2029. (Pubitemid 36197423)
25. Garrigue I, Doussau A, Asselineau J, et al. Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients. J Clin Microbiol. 2008;46(2):493-498. (Pubitemid 351231292)
26. Renneson J, Dutta B, Goriely S, et al. IL-12 and type I IFN response of neonatal myeloid DC to human CMV infection. Eur J Immunol. 2009;39(10):2789- 2799.
27. Chan G, Bivins-Smith ER, Smith MS, Smith PM, Yurochko AD. Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage. J Immunol. 2008;181(1):698-711.
28. Gerna G, Sarasini A, Patrone M, et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol. 2008;89(4):853-865.
29. Thedrez A, Sabourin C, Gertner J, et al. Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue? Immunol Rev. 2007;215:123-135. (Pubitemid 46212235)
30. Bonneville M, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol. 2010;10(7):467-478.
31. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity. 2009;31(2):184-196.
32. Rincon-Orozco B, Kunzmann V,Wrobel P, Kabelitz D, Steinle A, Herrmann T. Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol. 2005;175(4):2144-2151. (Pubitemid 41113819)
33. Wesch D, Beetz S, Oberg HH, Marget M, Krengel K, Kabelitz D. Direct costimulatory effect of TLR3 ligand poly(I:C) on human gamma delta T lymphocytes. J Immunol. 2006;176(3):1348-1354. (Pubitemid 43134276)
34. Lang P, Griesinger A, Hamprecht K, et al. Antiviral activity against CMV-infected fibroblasts in pediatric patients transplanted with CD34(+)-selected allografts from alternative donors. Hum Immunol. 2004;65(5):423-431. (Pubitemid 38686766)
35. McCormick AL. Control of apoptosis by human cytomegalovirus. Curr Top Microbiol Immunol. 2008;325:281-295.
36. Delmas S, Brousset P, Clement D, Le Roy E, Davignon JL. Anti-IE1 CD4+ T-cell clones kill peptide-pulsed, but not human cytomegalovirus-infected, target cells. J Gen Virol. 2007;88(9):2441-2449. (Pubitemid 47323889)
37. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99(3):754-758. (Pubitemid 34525533)
38. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14(4):778-809. (Pubitemid 32979631)
39. Kondadasula SV, Roda JM, Parihar R, et al. Colocalization of the IL-12 receptor and Fcgamma-RIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma. Blood. 2008;111(8):4173-4183.
40. Behr C, Capone M, Couzi L, Taupin JL, Dechanet-Merville J. Vdelta2neg gammadelta T cells, a multi-reactive tissue subset: from innate to adaptive altered-self surveillance. Open Immunol J. 2009;2:106-118.
41. Nigro G, Adler SP, La Torre R, Best AM. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med. 2005;353(13):1350-1362. (Pubitemid 41362703)
42. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377(9773):1256-1263.